SINUS-24 and SINUS-52

DUPIXENT 300 mg Q2W + INCS reduced polyp burden as early as Week 4, sustained through Week 52 in SINUS-52, compared to placebo + INCS.⁴

There was a reduction in bilateral NPS as follows:

• Week 4 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.18 (95% CI: -1.47, -0.90) (-1.13 from a baseline score of 6.07 vs 0.05 from a baseline score of 5.96, respectively)⁴
• Week 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -1.80 (95% CI: -2.10, -1.51) (-1.71 from a baseline score of 6.18 vs 0.10 from a baseline score of 5.96, respectively) (P<0.0001)^1,4
• Week 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -2.40 (95% CI: -2.77, -2.02) (-2.24 from a baseline score of 6.07 vs 0.15 from a baseline score of 5.96, respectively) (P<0.0001)⁴
• Week 24 in SINUS-24 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=143) and placebo + INCS (n=133): -2.06 (95% CI: -2.43, -1.69) (-1.89 from a baseline score of 5.64 vs 0.17 from a baseline score of 5.86, respectively) (P<0.0001)^1,4

Nasal polyp score (NPS), the sum of right and left nostril scores (range 0-4 for each nostril, range 0-8 in total) as evaluated by nasal endoscopy: reduced score indicates improvement.¹

INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

See what polyp reduction looks like with DUPIXENT